Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Sun Yat-sen University

Status: Completed

Conditions: Lung Cancer

Treatments: Drug: Immunotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06292052

NSCLC-TDLN-001

Details and patient eligibility

About

The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.

Enrollment: 209 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pathologically-confirmed diagnosis of NSCLC by pretreatment biopsy
• clinically staged as T1-4N0-2M0
• having undergo neoadjuvant chemoimmunotherapy
• the agents of immune checkpoint inhibitors (ICIs) belong to PD-1/L1 inhibitors
• having undergo surgery with lymph nodes (LNs) dissection
• having postoperative pathology reports with evaluation of primary tumor and LNs response
• having accessible pretreatment and preoperative radiology examinations imaging or reports

Exclusion criteria

• using PD-1/L1 inhibitors in the phase of clinical trials
• the agents of neoadjuvant therapy including angiogenesis inhibitors
• having undergone radiotherapy to treat primary tumor or metastatic LNs before surgery

Trial design

209 participants in 1 patient group

Neoadjuvant immunochemotherapy NSCLC group

Description:

NSCLC patients who received neoadjuvant immunochemotherapy and underwent surgery.

Treatment:

Drug: Immunotherapy